This is an observational single-center trial for patients with localized prostate cancer suitable for High Dose Rate (HDR) brachytherapy as monotherapy. This study takes a multi-omics approach to study the mechanism of action of HDR brachytherapy through metabolomics, immunological, transcriptomics, and spectroscopic profiling. The results of this study will clarify the optimal dose for HDR prostate brachytherapy by documenting the dose-response relationship seen in the changing tumor metabolites after HDR brachytherapy and investigate the immunogenicity of HDR brachytherapy.
Favorable risk and intermediate-risk prostate cancer with estimated life expectancy of at least 10 years.
Clinical stage T1c-T2b, PSA < 20, Gleason < 8
ECOG 0-1
Low tier intermediate-risk prostate cancer is defined by: a single NCCN intermediate risk factor (either Gleason 7(3+4) and PSA < 10 ng/ml OR Gleason 6 and PSA 10-20 ng/ml)
Prior radical surgery for carcinoma of the prostate,
Prior pelvic radiation
Prior chemotherapy for prostate cancer,
Claustrophobic or unable to undergo MRI
British Columbia Cancer Agency
Lead sponsor
BC Cancer Foundation
Collaborator
University of British Columbia
Collaborator
Vancouver Prostate Centre
Collaborator